Mengxia Yu

1.9k total citations
35 papers, 470 citations indexed

About

Mengxia Yu is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Mengxia Yu has authored 35 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 21 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in Mengxia Yu's work include Acute Myeloid Leukemia Research (22 papers), Histone Deacetylase Inhibitors Research (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Mengxia Yu is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Histone Deacetylase Inhibitors Research (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Mengxia Yu collaborates with scholars based in China and United States. Mengxia Yu's co-authors include Jie Jin, Chao Hu, Hongyan Tong, Jiansong Huang, Zhixin Ma, Yile Zhou, Yungui Wang, Shujuan Huang, Xia Li and Jinghan Wang and has published in prestigious journals such as Blood, PLoS ONE and Scientific Reports.

In The Last Decade

Mengxia Yu

34 papers receiving 466 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mengxia Yu China 15 282 204 93 90 87 35 470
Ajay Abraham United States 10 247 0.9× 172 0.8× 35 0.4× 86 1.0× 68 0.8× 30 389
Raquel Alves Portugal 13 196 0.7× 179 0.9× 63 0.7× 63 0.7× 111 1.3× 35 421
Ida Sofie Grønningsæter Norway 8 278 1.0× 177 0.9× 105 1.1× 50 0.6× 31 0.4× 9 404
Antonieta Chávez‐González Mexico 13 161 0.6× 178 0.9× 52 0.6× 65 0.7× 72 0.8× 37 402
Natasha S. Anstee Australia 11 193 0.7× 151 0.7× 38 0.4× 77 0.9× 59 0.7× 21 381
Christina Economopoulou Greece 8 221 0.8× 96 0.5× 58 0.6× 73 0.8× 99 1.1× 15 401
Ilaria Defilippi Italy 9 215 0.8× 312 1.5× 73 0.8× 56 0.6× 197 2.3× 21 501
Irene Gañán‐Gómez United States 11 351 1.2× 262 1.3× 84 0.9× 48 0.5× 75 0.9× 44 626

Countries citing papers authored by Mengxia Yu

Since Specialization
Citations

This map shows the geographic impact of Mengxia Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengxia Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengxia Yu more than expected).

Fields of papers citing papers by Mengxia Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mengxia Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengxia Yu. The network helps show where Mengxia Yu may publish in the future.

Co-authorship network of co-authors of Mengxia Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Mengxia Yu. A scholar is included among the top collaborators of Mengxia Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mengxia Yu. Mengxia Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pan, Jiajia, Yungui Wang, Shujuan Huang, et al.. (2024). High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response. Journal of Molecular Medicine. 102(3). 415–433. 5 indexed citations
2.
Li, Fenglin, et al.. (2023). High Expression of CD300A Predicts Poor Survival in Acute Myeloid Leukemia. Acta Haematologica. 146(3). 196–205. 4 indexed citations
3.
Yu, Mengxia, et al.. (2021). Anti-PD-1 Treatment-Induced Immediate Central Diabetes Insipidus: A Case Report. Immunotherapy. 13(15). 1255–1260. 12 indexed citations
4.
Hu, Chao, Mengxia Yu, Chenying Li, et al.. (2020). miR-550-1 functions as a tumor suppressor in acute myeloid leukemia via the hippo signaling pathway. International Journal of Biological Sciences. 16(15). 2853–2867. 14 indexed citations
5.
Yu, Mengxia, et al.. (2020). The relationship between consumption of nitrite or nitrate and risk of non-Hodgkin lymphoma. Scientific Reports. 10(1). 551–551. 10 indexed citations
6.
Huang, Shujuan, Mengxia Yu, Yile Zhou, et al.. (2020). Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma in vivo and vitro. Journal of Cancer. 11(8). 2123–2132. 22 indexed citations
7.
Huang, Shujuan, Jiajia Pan, Jing Jin, et al.. (2019). Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia. Cancer Letters. 461. 132–143. 18 indexed citations
8.
Mao, Shihui, Fenglin Li, Xia Li, et al.. (2019). A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells. Medical Oncology. 36(9). 77–77. 6 indexed citations
9.
Yan, Xiao, Yile Zhou, Shujuan Huang, et al.. (2018). Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma. Journal of Cancer Research and Clinical Oncology. 144(4). 697–706. 10 indexed citations
10.
11.
Wang, Jinghan, Fenglin Li, Zhixin Ma, et al.. (2018). High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. EBioMedicine. 28. 90–96. 30 indexed citations
12.
Hu, Chao, Mengxia Yu, Yanling Ren, et al.. (2017). PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Scientific Reports. 7(1). 2894–2894. 18 indexed citations
13.
Wang, Jinghan, et al.. (2016). Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia. 16(10). 577–581. 7 indexed citations
14.
Wang, Wei, Zhimei Chen, Mengxia Yu, et al.. (2015). [Clinical and cytogenetic study of chromosome 1 abnormality in myelodysplastic syndrome].. PubMed. 36(10). 818–23. 1 indexed citations
15.
Lu, Shasha, et al.. (2015). Overexpression of musashi2 is possibly associated with chemoresistance in T-cell acute lymphoblastic leukemia. Leukemia & lymphoma. 57(2). 467–469. 3 indexed citations
16.
Jin, Jie, Chao Hu, Mengxia Yu, et al.. (2014). Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis. PLoS ONE. 9(6). e100206–e100206. 47 indexed citations
17.
Mu, Qitian, Qiuling Ma, Shasha Lu, et al.. (2014). 10058-F4, a c-Myc inhibitor, markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells. Oncology Letters. 8(3). 1355–1359. 11 indexed citations
18.
Jin, Jie, Mengxia Yu, Chao Hu, et al.. (2014). Alcohol consumption and risk of myelodysplastic syndromes: A meta-analysis of epidemiological studies. Molecular and Clinical Oncology. 2(6). 1115–1120. 9 indexed citations
19.
Jin, Jie, Mengxia Yu, Chaosu Hu, et al.. (2014). Pesticide Exposure as a Risk Factor for Myelodysplastic Syndromes: A Meta-Analysis Based on 1,942 Cases and 5,359 Controls. PLoS ONE. 9(10). e110850–e110850. 21 indexed citations
20.
Tong, Hongyan, et al.. (2013). A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes. PLoS ONE. 8(6). e67537–e67537. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ajay Abraham Breakdown of academic impact, for papers by Raquel Alves Breakdown of academic impact, for papers by Ida Sofie Grønningsæter Breakdown of academic impact, for papers by Antonieta Chávez‐González Breakdown of academic impact, for papers by Natasha S. Anstee Breakdown of academic impact, for papers by Christina Economopoulou Breakdown of academic impact, for papers by Ilaria Defilippi Breakdown of academic impact, for papers by Irene Gañán‐Gómez
Rankless by CCL
2026